Self-immolative nanocapsules precisely regulate depressive neuronal microenvironment for synergistic antidepression therapy.

ABSTRACT:

Background

Pharmacotherapy constitutes the first-line treatment for depression. However, its clinical use is hindered by several limitations, such as time lag, side effects, and narrow therapeutic windows. Nanotechnology can be employed to shorten the onset time by ensuring permeation across the blood brain barrier (BBB) to precisely deliver more therapeutic agents; unfortunately, formidable challenges owing to the intrinsic shortcomings of commercial drugs remain.

Results

Based on the extraordinary capability of monoamines to regulate the neuronal environment, we engineer a network nanocapsule for delivering serotonin (5-hydroxytryptamine, 5-HT) and catalase (CAT) to the brain parenchyma for synergistic antidepression therapy. The nanoantidepressants are fabricated by the f

SUBMITTER: Liu Z 

PROVIDER: S-EPMC10433581 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature